The

European Medicines Agency

(EMA) opens the door to the emergency use of the antiviral molnupiravir against Covid-19.

This was announced at a press conference by Marco Cavaleri, head of Biological Products and Vaccine Strategy at the EMA.

The European body is reviewing the data of this MSD drug which, according to the data provided by the pharmaceutical company, is capable of halving the risk of death and hospitalization from Covid. While experts reach a conclusion on the drug, the EMA has decided to expedite access to treatment by giving the EU member states a free pass to authorize its use under the

emergency route.

The EMA "is prepared to advise member states so that they

can make this treatment available for emergency use

, before it receives its commercial authorization," said Cavaleri, who explained that the decision to favor emergency use The drug must be interpreted in the context of the new increase in cases that many European countries are experiencing.

The EMA's decision coincides with the authorization of

molnupiravir

by the UK regulatory authorities.

The United Kingdom is, at the moment, the only country that has approved the use of the antiviral.

Molnupiravir is an

antiviral drug

that in a phase 3 clinical study (in 775 patients) conducted by MSD has shown to halve the risk of hospitalization and death in adult patients at risk of developing severe Covid.

According to the criteria of The Trust Project

Know more

See links of interest

  • The Palm

  • Georgie Dann dies

  • Last News

  • What

  • Holidays 2021

  • 2022 business calendar

  • Master Investigation Journalism

  • Time change

  • Christmas Lottery 2021

  • Loteria del Niño 2022

  • Milan - FC Porto

  • Real Madrid - Shakhtar Donetsk

  • Borussia Dortmund - Ajax

  • Liverpool - Atlético de Madrid

  • Manchester City - Club Brugge